All In Biotech

Drug Trial Radar · NCT07015268

A Clinical Study of KLH-2109 in Patients With Endometriosis

Phase III Confirmatory Study of KLH-2109 in Patients With Endometriosis

Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 288 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

288

Planned (sponsor's estimate)

Start

Jun 9, 2025

Primary completion

Nov 2027

Study completion Nov 2027

Sponsor

Sponsor type
Industry
First posted
Jun 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To verify the non-inferiority of KLH-2109 to leuprorelin acetate in a double-blind manner in terms of efficacy in endometriosis patients with pelvic pain.

Conditions

  • Endometriosis

Interventions

  • KLH-2109Drug

    \- KLH-2109 tablet: Oral administration \- Leuprorelin acetate placebo: Subcutaneous administration

  • Leuprorelin acetateDrug

    \- KLH-2109 placebo tablet: Oral administration \- Leuprorelin acetate: Subcutaneous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the maximum NRS score for pelvic pain during 28 days prior to 12 weeks of the investigational product treatmentTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Multiple Locations, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.